CD127-Low Treg Isolation for Accurate FoxP3-Enriched Cell Sorting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of specific cell surface biomarkers for regulatory T cells (Tregs) in humans complicates their identification and isolation, limiting therapeutic interventions for autoimmune diseases and other immune disorders, as existing markers like CD25 and CTLA-4 are also expressed on effector T cells, and intracellular markers like FoxP3 are not suitable for functional studies or expansion.
Innovation Solution
Utilizing CD127 as a biomarker to identify and isolate immunosuppressive regulatory T cells, particularly FoxP3+ Tregs, by detecting reduced CD127 expression, either alone or in conjunction with other markers, to enrich for CD4+CD127lo/− or CD8+CD127lo/− T cells, which are highly likely to be immunosuppressive.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CD25 and CTLA-4 are used as biomarkers for Tregs, then Treg identification is possible, but the markers are also expressed on effector T cells making identification problematic
Solution Approach 1:
Instead of using markers that are highly expressed on Tregs (CD25, CTLA-4), the patent inverts the approach by using a marker (CD127) that is characteristically downregulated or absent on Tregs. This allows Tregs to be identified by their lack of CD127 expression, providing specificity that overcomes the problem of overlapping marker expression with effector T cells.
Solution Approach 2:
The patent applies local quality by examining CD127 expression at different levels (high, intermediate, low/absent) to distinguish Treg subsets. By focusing on the specific local characteristic of CD127 downregulation rather than general marker presence, the method achieves precise Treg identification despite the non-specificity of traditional markers.
2Measurement precision
If FoxP3 is used as a marker for Tregs, then Treg identification is accurate, but the intracellular marker cannot be used for functional studies or expansion
Solution Approach 1:
The patent uses CD127 as an intermediary marker that bridges the gap between intracellular FoxP3 detection and functional studies. By using CD127 expression patterns (particularly low/absent expression) as a surrogate marker, the method enables flow cytometry-based identification and functional analysis without requiring direct FoxP3 staining, thus facilitating both identification and operational feasibility.
3Measurement precision
If CD4+CD25hi Tregs are isolated using traditional markers, then Treg population is identified, but only limited numbers of cells can be isolated from peripheral blood
Solution Approach 1:
The patent changes the selection parameter from CD25 high expression to CD127 low/absent expression. This parameter change expands the identifiable Treg population, allowing isolation of up to 7-8% of CD4+ T cells as Tregs, significantly increasing the cell yield from peripheral blood compared to traditional CD25-based methods.
Data Source
AI summary
The invention provides methods of isolating CD127lo/− immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.